Abstract
ABSTRACT
Introduction: peripartum cardiomyopathy is a clinical condition underestimated, leading to a forgotten it, with a delay in diagnosis and treatment and thus to high rates of morbidity and mortality entity. The diagnosis is based on clinical signs and symptoms, plus evidence of heart failure that develops during the last month of pregnancy and the first five months postpartum echocardiography evidenced a left ventricular dysfunction. Objective: a current review of the different components of the disease, from the epidemiology, etiology, pathophysiology, clinical advances in diagnosis and treatment. Searching methodology: a search was performed in multiple databases such as PubMed, Cochrane, Sciencedirect and academic Google; where 96 articles were found, 38 were selected ruling out several items that did not meet inclusion criteria. Results: the most current databases of information found was chosen, 55 articles were selected and classification, etiology, pathophysiology, diagnosis, treatment and prognosis were reviewed. Conclusions: peripartum cardiomyopathy remains a major medical diagnosis and treatment for all large multidisciplinary team challenge; there must be a suspicion diagnosis to initiate appropriate and timely treatment approach wherein a decrease in morbidity and mortality can be achieved for both mother and fetus. There are new developments for the treatment of surgically, that help improve the quality of life for women who are with
subsequent heart failure. MÉD.UIS. 2016;29(2):103-11.
Keywords: Cardiomyopathy. Pregnancy Complications. Heart Failure. Prolactin. /Diagnosis. Therapeutics.
References
Sliwa K, Hilfiker-Kleiner D, Mebazaa A, Petrie MC, Maggioni AP, Regitz-Zagrosek V, et al. EURObservational research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. Eur J Heart Fail. 2014;16(5):583-91.
Ramírez EM. Miocardiopatía periparto. Revista médica de costa rica y Centroamérica. 2013;LXX(607):449-55.
Elkayam U, Jalnapurkar S, Barakat M. Peripartum Cardiomyopathy. Cardiol Clin. 2012;30(3):435–40.
Monsalve G, Martínez C, Gallo T, González MV, Arango G, Upegui Al, et al . Paciente embarazada con enfermedad cardiaca: Manejo periparto basado en la estratificación del riesgo. Serie de casos 2005-2009. Rev. colomb. Anestesiol. 2010;38(3):348-60.
Bozkurt B, Villaneuva FS, Holubkov R, Tokarczyk T, Alvarez RJ Jr, MacGowan GA, et al. Intravenous Immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol. 1999;34(1):177-80.
Mielniczuk LM, Williams K, Davis DR, Tang AS, Lemery R, Green MS, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006;97(12):1765-8.
Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58(7):659-70.
Hernández A, Nieto AJ, Medina V, Delgado J. Cardiomiopatía periparto: reporte de un caso y revisión de la literatura. Rev. Colomb Obstet Ginecol. 2009;60(3):294-9.
Laverde CE, Garnica LM, Correa N. Informe de caso sobre cardiomiopatía periparto: rara, desconocida y potencialmente fatal. Rev. Col. Anest. 2016;44(1):63-8.
Lewey J, Haythe J. Cardiomyopathy in pregnancy. Semin Perinatol. 2014;38(5):309-17. [Artículo de revista]
Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006;368(9536):687-93.
Bollen IA, Van Deel ED, Kuster DW, Van Der VJ. Peripartum cardiomyopathy and dilated cardiomyopathy: different at heart. Front Physiol. 2015;15:531.
Bello NA, Arany Z. Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis. Trends Cardiovasc Med. 2015;25(6):499-504.
Yamac H, Bultmann I, Sliwa K, Hilfiker-Kleiner D. Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart. 2010;96(17):1352-7.
McGregor AJ, Barron R, Rosene-Montella K. The pregnant heart: cardiac emergencies during pregnancy. Am J Emerg Med. 2015;33(4):573-9.
Horne BD, Rasmusson KD, Alharethi R, Budge D, Brunisholz KD, Carlquist JF, et al. Peripartum cardiomyopathy-associated sequence variant at the PTHLH locus is not predictive of idiopathic or ischemic cardiomyopathy. Circulation. 011;124:A16347.
Gleicher N, and Elkayam U. Peripartum cardiomyopathy, an autoimmune manifestation of allograft rejection?. Autoimmun Rev. 2009;8(5):384-7.
Ntobeko B. A. Ntusi1, Motasim Badri1, Freedom Gumedze. Pregnancy-Associated Heart Failure: A Comparison of Clinical Presentation and Outcome between Hypertensive Heart Failure of Pregnancy and Idiopathic Peripartum Cardiomyopathy. PLoS One. 2015;10(8):e0133466.
Polanía DF, Navarrete S, Acuña EM, Álvarez RA. Miocardiopatía periparto. Insuficiencia Cardiaca. 2009;4(4): 177-83.
Velásquez JE, Duque M. Cardiomiopatía periparto. Rev. Colomb Cardiol. 2008;15(1):5-11.
McGregor AJ, Barron R, Rosene-Montella K. The pregnant heart: cardiac emergencies during pregnancy. Am J Emerg Med
;33(4):573-9 .
Givertz MM. Peripartum Cardiomyopathy. Circulation 2013;127:622-6.
Dennis AT, Castro JM. Echocardiographic differences between preeclampsia and peripartum cardiomyopathy. Int J Obstet Anesth 2014;23(3):260-6.
Sliwa K, Hilfiker-Kleiner D, Mebazaa A, Petrie MC, MaggionAP, Regitz- grosek V, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12(8):767-78.
Altun I, Akin F, Basaran O, Biteker M. Management of peripartum cardiomyopathy. Int J Cardiol 2014;177(2):714.
Mouquet F, Lions C, de Groote P, Bouabdallaoui N, Willoteaux S,
Dagorn J et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol 2008;18(12):2765–9.
Johnson-Coyle L, Jensen L, Sobey A. Perimartum cardiomyoparhy: Review and practice guildenes. Am J Crit Care 2012;21(2):89-98.
Karaye KM, Henein MY. Peripartum cardiomyopathy: A review article. Int J Cardiol 2013;164(1):33-8.
Demir S, Tufenk M, Karakaya Z, Akilli R, Kanadas M. The Treatment of Heart Failure-Related Symptoms with Ivabradine in a Case with Peripartum Cardiomyopathy. Int Cardiovasc Res J 2013;7(1):33–6.
Desplantie O, Tremblay-Gravel M, Avram R, Marquis-Gravel G, Ducharme A, Jolicoeur EM. The Medical Treatment of NewOnset Peripartum cardiomyopathy: A Systematic Review of Prospective Studies. Can J Cardiol 2015;31(12):1421-6.
Pillarisetti J, Kondur A, Alani A, Reddy M, Reddy M, Vacek J et al. Peripartum Cardiomyopathy Predictors of Recovery and Current State of Implantable Cardioverter-Defibrillator Use. J Am Coll Cardiol. 2014;63:2831-9.
Yıldırım B, Basaran O, Soylu MO, Altun I, iteker B. Inadequately investigated drugs in acute peripartum cardiomyopathy. Int J Cardiol 2015;189:198.
Yamada T1, McElderry HT, Muto M, Okada T, Murakami Y, Doppalapudi H et al. Ventricular arrhythmias originating from the epicardial ventricular outflowtract complicated with peripartum cardiomyopathy. J Interv Card Electrophysiol 2009;25(1):53-7.
Duran N, Günes H, Duran I, Biteker M, Ozkan M. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet. 2008;101(2):137-40.
Ramaraj R, Sorrell VL. Miocardiopatía del periparto. J Med 2009;76: 289-296.
Margarita A, Peradejordi, Liliana E, Favaloro, Bertolotti A, Absi D, Vigliano C. Predictores de mortalidad o trasplante cardíaco en la miocardiopatía periparto. Rev. argent. cardiol. 2013;81:45-52.
Barasa A, Rosengren BA, Ladfors L, Swedberg K, Schaufelberger M. Longterm mortality in 272 women with peripartum cardiomyopathy. Circulation 2012;126.
Velásquez JE, Duque M. Cardiomiopatía periparto. Rev. Col. Cardiol 2008;15(1):5-11.